Supernus Pharmaceuticals
SUPN
208 hedge funds and large institutions have $895M invested in Supernus Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 66 increasing their positions, 87 reducing their positions, and 47 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less call options, than puts
Call options by funds: $2.35M | Put options by funds: $2.36M
3.64% less ownership
Funds ownership: 97.81% → 94.17% (-3.6%)
11% less funds holding
Funds holding: 235 → 208 (-27)
24% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 87
26% less capital invested
Capital invested by funds: $1.22B → $895M (-$322M)
49% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$27.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.08M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.28M |
| 4 |
Two Sigma Advisers
New York
|
+$5.26M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$20.4M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$17.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.06M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$5.43M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.22M |
SUPN Hedge Fund Activity: Q1 2020 in Review
208 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2020, worth a combined $895M — down 26% from $1.22B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of SUPN and 24 opened new positions — a net loss of 23 holders — while 87 trimmed existing stakes and 66 added.
The largest buyer was Armistice Capital, adding an estimated $27.1M. The largest seller was Millennium Management, exiting entirely with an estimated $20.4M sold.
- 208 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2020, down from 235 in Q4 2019.
- Funds reported $895M of Supernus Pharmaceuticals stock for Q1 2020, down 26% quarter-over-quarter.
- 24 funds opened new Supernus Pharmaceuticals positions in Q1 2020 and 47 closed out, a net change of -23 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2020 was Armistice Capital, an estimated $27.1M added.
- The largest Supernus Pharmaceuticals seller in Q1 2020 was Millennium Management, an estimated $20.4M sold.
Based on aggregated 13F filings for Q1 2020.